These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 27534869

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cytochrome oxidase 2D6 gene polymorphism in primary open-angle glaucoma with various effects to ophthalmic timolol.
    Yang Y, Wu K, Yuan H, Yu M.
    J Ocul Pharmacol Ther; 2009 Apr; 25(2):163-71. PubMed ID: 19284319
    [Abstract] [Full Text] [Related]

  • 4. Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops.
    Mäenpää J, Volotinen-Maja M, Kautiainen H, Neuvonen M, Niemi M, Neuvonen PJ, Backman JT.
    Drug Metab Dispos; 2014 Dec; 42(12):2068-76. PubMed ID: 25261563
    [Abstract] [Full Text] [Related]

  • 5. Symptomatic bradycardia secondary to interaction between topical timolol maleate, verapamil, and flecainide: a case report.
    Minish T, Herd A.
    J Emerg Med; 2002 Apr; 22(3):247-9. PubMed ID: 11932086
    [Abstract] [Full Text] [Related]

  • 6. New technique to reduce systemic side effects of timolol eye drops: The tissue press method-Cross-over clinical trial.
    Müller L, Jensen BP, Bachmann LM, Wong D, Wells AP.
    Clin Exp Ophthalmol; 2020 Jan; 48(1):24-30. PubMed ID: 31525271
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects.
    Nieminen T, Lehtimäki T, Mäenpää J, Ropo A, Uusitalo H, Kähönen M.
    Scand J Clin Lab Invest; 2007 Jan; 67(2):237-45. PubMed ID: 17366003
    [Abstract] [Full Text] [Related]

  • 9. Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes.
    Volotinen M, Korjamo T, Tolonen A, Turpeinen M, Pelkonen O, Hakkola J, Mäenpää J.
    Basic Clin Pharmacol Toxicol; 2010 Apr; 106(4):302-9. PubMed ID: 19912165
    [Abstract] [Full Text] [Related]

  • 10. Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolising variants.
    Epperla N, Brilliant MH, Vidaillet H.
    BMJ Case Rep; 2014 Feb 11; 2014():. PubMed ID: 24518395
    [Abstract] [Full Text] [Related]

  • 11. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction.
    Edeki TI, He H, Wood AJ.
    JAMA; 2014 Feb 11; 274(20):1611-3. PubMed ID: 7474246
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of risk of falls and orthostatic hypotension in older, long-term topical beta-blocker users.
    Ramdas WD, van der Velde N, van der Cammen TJ, Wolfs RC.
    Graefes Arch Clin Exp Ophthalmol; 2009 Sep 11; 247(9):1235-41. PubMed ID: 19452162
    [Abstract] [Full Text] [Related]

  • 13. [SYNCOPE CAUSED BY INTRA-OCULAR TIMOLOL].
    Eyal A, Braun E, Naffaa ME.
    Harefuah; 2015 Nov 11; 154(11):701-2, 742. PubMed ID: 26821501
    [Abstract] [Full Text] [Related]

  • 14. [Adverse effects of local use of beta-blockaders in glaucoma. A literature review and a survey of reports to the adverse drug reaction authority 1986-95].
    Nygaard HA, Høvding G.
    Tidsskr Nor Laegeforen; 1997 May 30; 117(14):2019-21. PubMed ID: 9235677
    [Abstract] [Full Text] [Related]

  • 15. Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study.
    Nieminen T, Uusitalo H, Mäenpää J, Turjanmaa V, Rane A, Lundgren S, Ropo A, Rontu R, Lehtimäki T, Kähönen M.
    Eur J Clin Pharmacol; 2005 Dec 30; 61(11):811-9. PubMed ID: 16315032
    [Abstract] [Full Text] [Related]

  • 16. Effect of CYP2D6*4, CYP2D6*10 polymorphisms on the safety of treatment with timolol maleate in patients with glaucoma.
    Moshetova LK, Soshina MM, Turkina KI, Grishina EA, Sozaeva ZA, Kachanova AA, Akmalova KA, Ivashchenko DV, Zastrozhin MS, Fisenko VP, Sychev DA.
    Drug Metab Pers Ther; 2023 Jun 01; 38(2):143-148. PubMed ID: 36001461
    [Abstract] [Full Text] [Related]

  • 17. Lichenoid drug eruption secondary to topical timolol and dorzolamide eye-drops.
    Mullins RJ, Lones R, Dutta B.
    Australas J Dermatol; 2004 May 01; 45(2):151-2. PubMed ID: 15068470
    [No Abstract] [Full Text] [Related]

  • 18. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma.
    Schenker H, Maloney S, Liss C, Gormley G, Hartenbaum D.
    Clin Ther; 1999 Jan 01; 21(1):138-47. PubMed ID: 10090431
    [Abstract] [Full Text] [Related]

  • 19. Cardiac failure aggravated by timolol eye drops: preoperative improvement by changing to pilocarpine.
    Bäcklund M, Kirvelă M, Lindgren L.
    Acta Anaesthesiol Scand; 1996 Mar 01; 40(3):379-81. PubMed ID: 8721473
    [Abstract] [Full Text] [Related]

  • 20. The safety of topical beta-blockers in glaucoma treatment.
    Goldberg I.
    Med J Aust; 1996 Apr 15; 164(8):498-9. PubMed ID: 8614346
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.